These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 3152555)

  • 21. [Relationship between antiplasmin capacity and concentration of alpha 2-plasmin inhibitor, alpha 2-macroglobulin, alpha 1-antitrypsin, antithrombin III or C1-inactivator in plasma of patients with transient ischemic attacks (author's transl)].
    Matsuda T; Seki T; Miura R; Ogawara M; Yokouchi M; Yamanouchi H
    Rinsho Byori; 1980 Mar; 28(3):261-4. PubMed ID: 6154815
    [No Abstract]   [Full Text] [Related]  

  • 22. Role of Lys335 in the metastability and function of inhibitory serpins.
    Im H; Yu MH
    Protein Sci; 2000 May; 9(5):934-41. PubMed ID: 10850803
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The role of conformational change in serpin structure and function.
    Gettins P; Patston PA; Schapira M
    Bioessays; 1993 Jul; 15(7):461-7. PubMed ID: 8379949
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Inhibitors of serum proteinases].
    Jendryczko A; Drózdz M
    Wiad Lek; 1985 Dec; 38(23):1654-9. PubMed ID: 2421489
    [No Abstract]   [Full Text] [Related]  

  • 25. The cowpox virus serpin SPI-3 complexes with and inhibits urokinase-type and tissue-type plasminogen activators and plasmin.
    Turner PC; Baquero MT; Yuan S; Thoennes SR; Moyer RW
    Virology; 2000 Jul; 272(2):267-80. PubMed ID: 10873770
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Role of the P6-P3' region of the serpin reactive loop in the formation and breakdown of the inhibitory complex.
    Plotnick MI; Schechter NM; Wang ZM; Liu X; Rubin H
    Biochemistry; 1997 Nov; 36(47):14601-8. PubMed ID: 9398179
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin.
    Whisstock JC; Skinner R; Carrell RW; Lesk AM
    J Mol Biol; 2000 Feb; 296(2):685-99. PubMed ID: 10669617
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Conformational changes in serpins: I. The native and cleaved conformations of alpha(1)-antitrypsin.
    Whisstock JC; Skinner R; Carrell RW; Lesk AM
    J Mol Biol; 2000 Jan; 295(3):651-65. PubMed ID: 10623554
    [TBL] [Abstract][Full Text] [Related]  

  • 29. C1-inhibitor: structure/function and biologic role.
    Aulak KS; Donaldson VH; Coutinho M; Davis AE
    Behring Inst Mitt; 1993 Dec; (93):204-13. PubMed ID: 8172569
    [No Abstract]   [Full Text] [Related]  

  • 30. Inactivation of factor Xia in vivo: studies in chimpanzees and in humans.
    Wuillemin WA; Hack CE; Bleeker WK; Biemond BJ; Levi M; ten Cate H
    Thromb Haemost; 1996 Oct; 76(4):549-55. PubMed ID: 8902995
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The isoelectric focusing pattern of desialylated alpha 1-antichymotrypsin of heterozygous alpha 1-antichymotrypsin deficiency and of acute phase plasma.
    Lindmark B; Kamiguchi H; Tsuda M; Yamamura M
    Tokai J Exp Clin Med; 1990 Jul; 15(4):347-51. PubMed ID: 2130541
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Heparin-stimulated modification of C1-inhibitor by subcomponent C1s of human complement.
    Weiss V; Engel J
    Hoppe Seylers Z Physiol Chem; 1983 Mar; 364(3):295-301. PubMed ID: 6602754
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Hepatocyte uptake of alpha 1-proteinase inhibitor-trypsin complexes in vitro: evidence for a shared uptake mechanism for proteinase complexes of alpha 1-proteinase inhibitor and antithrombin III.
    Fuchs HE; Michalopoulos GK; Pizzo SV
    J Cell Biochem; 1984; 25(4):231-43. PubMed ID: 6334690
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Proteolytic enzymes and catabolism: enhanced release of granulocyte proteinases in uremic intoxication and during hemodialysis.
    Heidland A; Hörl WH; Heller N; Heine H; Neumann S; Heidbreder E
    Kidney Int Suppl; 1983 Dec; 16():S27-36. PubMed ID: 6376917
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Evaluation of platelet activation, plasma antithrombin III and alpha2-antiplasmin activities in hypertensive patients.
    Tomczykowska M; Bielak J; Bodys A
    Ann Univ Mariae Curie Sklodowska Med; 2003; 58(1):15-20. PubMed ID: 15314952
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Proteases and protease inhibitors in taurocholate-induced acute pancreatitis in rats.
    Kruse P; Hage E; Lasson A
    Int J Pancreatol; 1999 Apr; 25(2):113-21. PubMed ID: 10360224
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Protease inhibitors].
    Lambin P
    Rev Fr Transfus Immunohematol; 1980 May; 23(2):147-83. PubMed ID: 6161406
    [No Abstract]   [Full Text] [Related]  

  • 38. Crucial residues in the carboxy-terminal end of C1 inhibitor revealed by pathogenic mutants impaired in secretion or function.
    Verpy E; Couture-Tosi E; Eldering E; Lopez-Trascasa M; Späth P; Meo T; Tosi M
    J Clin Invest; 1995 Jan; 95(1):350-9. PubMed ID: 7814636
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Purification of proplatelet formation (PPF) stimulating factor: thrombin/antithrombin III complex stimulates PPF of megakaryocytes in vitro and platelet production in vivo.
    Ishida Y; Yano K; Ito T; Shigematus H; Sasaki K; Kondo S; Kuriya S
    Thromb Haemost; 2001 Feb; 85(2):349-55. PubMed ID: 11246559
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Protease inhibitor and gastric cancer.
    Tsumoto S; Oyabu H; Kageyama T
    Bull Osaka Med Sch; 1983 Jul; 29(1):18-26. PubMed ID: 6204707
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.